ClinicalTrials.gg
Sign In
Drug

PD-L1 Inhibitor INCB099280 clinical trials

Also written INCB099280.

studies test it
8
open now
0
in phase 3
0
first study started
2020

How each study uses PD-L1 Inhibitor INCB099280 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

INCB099280
7

Studies by the year they started

8 studies that test it; most in 2023 (4)

Studies that test PD-L1 Inhibitor INCB099280, by start year
YearStudies
20201
20234
20243

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Melanoma
1
Carcinoma, Hepatocellular
1

Who runs them

Industry 7 · Other 1

Incyte Corporation (7) · Abramson Cancer Center at Penn Medicine (1)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses PD-L1 Inhibitor INCB099280 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 8

What changed recently

From the registry's own updates since Oct 14, 2026.

Stopped2